Signals Of EPZ5676 You Ought To Know

ine.es). The two mentioned centers assume the http://www.selleck.cn/products/Staurosporine.html treatment of all AML patients. The FLAGIDA-lite protocol was as follows: fludarabine (orally, 40 mg/m2 daily, days 1�C5), cytarabine (subcutaneously, 20 mg/m2 daily, days 1�C5), idarrubicin (orally, 15 mg/m2 daily, days 1�C3), and G-CSF (subcutaneously, 300 ��g daily, days 1�C5). Patients who presented an absolute peripheral leukocyte count > 100 �� 109/L were treated with hydroxyurea and leukapheresis prior to starting the FLAGIDA-lite until the absolute peripheral leukocyte count was http://www.selleckchem.com/products/epz-5676.html and social support. Cell blood counts and basic serum chemistry were carried out daily in inpatients and in home care patients and twice weekly in ambulatory patients. The cytogenetic risk allocation followed the Medical Research Council criteria [22]. Disease response was assessed by bone marrow aspirates collected after each cycle recovery, and then as clinically indicated, using the European LeukemiaNet criteria [23]. OS and RFS were estimated by the Kaplan-Meier method, following the European LeukemiaNet definitions. IRM was defined http://www.selleckchem.com/products/ly2109761.html as the 4-week mortality after an induction cycle. The influence of clinical characteristics on outcome was estimated by the log-rank test, and proportions and means were compared by the Fisher exact test and the Mann-Whitney U-test, respectively. The SPSS v 16.0 software was used for these estimates. From January 2006 to December 2010 we diagnosed 50 new cases of AML or RAEB-2 in patients older than 70 years of age. Eight patients were not enrolled due to a poor performance status (ECOG 4) or the coexistence of very severe illness and four patients refused treatment. Thirty-eight patients were enrolled in the study. Their characteristics are shown in Table I. Median age was 78 years (range, 71�C91 years) with 34% patients older than 80 years. ECOG performance status index was 0-2 in 92% and Charlson comorbidity index was high/very high in 79%. According to the WHO criteria, there were 32 AML cases (AML with myelodysplasia-related changes 16, therapy-related myeloid neoplasia 2, AML not otherwise specified 14) and six RAEB-2 cases. AML was ��de novo�� in 14 patients and secondary in 18. Twenty-four AML cases and all six RAEB-2 cases had intermediate or high risk cytogenetics.